Otsuka completes shift to new holding structure
This article was originally published in Scrip
Otsukahas completed an internal share transfer and restructuring which has resulted in the formation of a new holding entity which is to oversee all of the private Japanese group's diversified global operations, including its mainstay prescription drug business Otsuka Pharmaceutical.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.